Synergistic induction of hl60 cell differentiation by ketoconazole and 1-desoxy analogues of Vitamin D3

Journal of the National Cancer Institute

Volumn 89, Issue 16, 1997, Pages 1199-1206

  Wang, Xuening ^a   Gardner, Jeffrey P ^a   Kheir, Ahmed ^a   Uskokovic, Milan R ^b   Studzinski, George P ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXY 16 ENE 23 YNE VITAMIN D3; 25 HYDROXY DIENE 26,27 HEXAFLUORO VITAMIN D3; 25 HYDROXYDIENE VITAMIN D3; CALCIFEDIOL; CALCITRIOL; COLECALCIFEROL DERIVATIVE; KETOCONAZOLE; RO 24 2090; RO 24 2287; RO 25 9887; RO 88892; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA; MYELOID LEUKEMIA;

EID: 0030800143     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.16.1199     Document Type: Article

References (54)

1. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72:567-72.
2. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
3. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991;324:1385-93.
4. Studzinski GP, McLane JA, Uskokovic MR. Signaling pathways for vitamin D-induced differentiation: implications for therapy of proliferative and neoplastic diseases. Crit Rev Eukaryot Gene Expr 1993;3:279-312.
5. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-57.
6. Vieth R. The mechanisms of vitamin D toxicity. Bone Miner 1990;11: 267-72.
7. Stumpf WE, Sar M, Reid FA, Tanaka Y, DeLuca HF. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979,206:1188-90.
8. Haussler MR. Vitamin D receptors: nature and function. Annu Rev Nutr 1986;6:527-62.
9. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E, Ikeda K. A novel , vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3 inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991;129:832-7.
10. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K. Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 1993;52:2534-7.
11. Binderup S, Latini E, Binderup E, Bretting C, Calverley M, Hansen K. 20-Epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 1991;42:1569-75.
12. Colston KW, Mackay AG, James SY, Binderup L, Chander S, Coombes PC. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 1992;44:2273-80.
13. Zhou JY, Norman AW, Akashi M, Chen DL, Uskokovic MR, Aurrecoechea JM, et al. Development of a novel 1,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 1991;73:75-82.
14. Gardner JP, Zhang F, Uskokovic MR, Studzinski GP. Vitamin D analog 25-(OH)-16,23E-diene-26,27-hexafluoro-vitamin D3 induces differentiation of HL60 cells with minimal effects on cellular calcium homeostasis. J Cell Biochem 1996;63:500-12.
15. Uskokovic MR, Studzinski GP, Gardner JP, Reddy SG, Campbell MJ, Koeffler PH. The 16-ene vitamin D analogs. Curr Pharmaceut Design 1997;3:99-123.
16. Zhou JY, Norman AW, Chen DL, Sun GW, Uskokovic MR, Koeffler HP. 1,25-Dihydroxy-16-ene-23-yne-vitamin D3 prolongs survival time of leukemia mice. Proc Natl Acad Sci U S A 1990;87:3929-32.
17. Wilkinson CF, Hetnarski K, Yellin TO. Imidazole derivatives - a new class of microsomal enzyme inhibitors. Biochem Pharmacol 1972;21:3187-92.
18. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev 1986;7:409-20.
19. Brown AJ, Berkoben M, Ritter CS, Slatopolsky E. Binding and metabolism of 1,25-dihydroxyvitamin D3 in cultured bovine parathyroid cells. Endocrinology 1992;130:276-81.
20. 2+ influx. Biochem J 1991;274(Pt 1):193-7.
21. 2+ stores. Biochem J l993;289(Pt 3): 761-6.
22. Koch BD, Faurot GF, Kopanitsa MV, Swinney DC. Pharmacology of a Ca2+-influx pathway activated by emptying the intracellular Ca2+ stores in HL-60 cells: evidence That a cytochrome P-450 is not involved. Biochein J 1994;362(Pt 1):187-90.
23. Baggiolini EG, Iacobelli JA, Hennessy BM, Batcho AD, Sereno JF, Uskokovic MR. Stereocontrolled total synthesis of 1α-25-dihydroxy-cholecalciferol and 1α,25-dihydroxyergocalciferol. J Organic Chem 1986; 51:3098-108.
24. Godyn JJ, Xu HM, Zhang F, Kolla SS, Studzinski GP, A dual block to cell cycle progression in HL60 cells exposed to analogs of vitamin D3. Cell Prolif 1994;27:37-46.
25. 2+ influx mediated by store-operated channels in HL60 cells induced to differentiate by 1α,25-dihydroxyvitamin D3. J Cell Physiol 1997;172: 284-95.
26. Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplasmic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 1991;266:17067-71.
27. Favre CJ, Jerstrom P, Foti M, Stendhal O, Huggler E, Lew DP, et al. Organization of Ca2+ stores in myeloid cells: association of SERCA2b and the type-1 inositol-1,4,5-trisphosphate receptor. Biochem J 1996;316: 137-42.
28. Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 1981;68:932-41.
29. Griffin JD, Mayer RJ, Weinstein HJ, Rosenthal DS, Coral FS, Beveridge RP, et al. Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotype. Blood 1983;62:557-63.
30. Yam LT, Li CY, Crosby WH. Cytochemical identification of monocytes and granulocytes. Am J Clin Pathol 1971;55:283-90.
31. 0 phase cell cycle block. Cell Prolif 1994;27:643-54.
32. Wang QM, Jones JB, Studzinski GP, The cyclin-dependent kinase inhibitor p27 as a mediator of the G1-S phase block induced by 1,25-dihydroxy-vitamin D3 in HL60 cells. Cancer Res 1996;56:264-7.
33. Liu M, Lee MH, Cohen M, Bommakanti M, Freedman LP. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes Dev 1996;10: 142-53.
34. Reitsma PH, Rothberg PG, Astrin SM, Trial J, Bar-Shavit Z, Kahn AJ, et al. Regulation of myc gene expression in HL-60 leukemia cells by a vitamin D metabolite. Nature 1983;306:492-4.
35. Simpson RU, Hsu T, Begley DA, Mitchell BS, Alizadeh BN. Transcriptional regulation of the c-myc protooncogene by 1,25-dihydroxyvitamin D3 in HL-60 promyelocytic leukemia cells. J Biol Chem 1987;262:4104-8.
36. Larsson LG, Pettersson M, Oberg F, Nilsson K, Luscher B. Expression of mad, mxil, max and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 1994;9:1247-52.
37. Hruska KA, Bar-Shavit R, Malone JD, Teitelbaum S. Ca2+ priming during vitamin D-induced monocytic differentiation of a human leukemia cell line. J Biol Chem 1988;263:16039-44.
38. (24) gene. Nucleic Acids Res 1994;22:2410-6.
39. Tam SP, Strugnell S, Deeley RG, Jones G. 25-Hydroxylation of vitamin D3 in the human hepatoma cell lines Hep G2 and Hep 3B. J Lipid Res 1988; 29:1637-42.
40. Tomita S, Ohnishi J, Nakano M, lchikawa Y. The effects of anticonvulsant drugs on vitamin D3-activating cytochrome P-450-linked monooxygenase systems. J Steroid Biochem Mol Biol 1991;39:479-85.
41. Chen ML, Boltz MA, Armbrecht HJ. Effects of 1,25-dihydroxyvitamin D3 and phorbol ester on 25-hydroxyvitamin D3 24-hydroxylase cytochrome P450 messenger ribonucleic acid levels in primary cultures of rat renal cells. Endocrinology 1993;132:1782-8.
42. Henry HL. Effect of ketoconazole and miconazole on 25-hydroxyvitamin D3 metabolism by cultured chick kidney cells. J Steroid Biochem 1985; 23:991-4.
43. Glass AR, Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxy vitamin D. J Clin Endocrinol Metab 1986;63:766-9.
44. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest 1983;71:1495-9.
45. Reinhardt TA, Horst RL, Ketoconazole inhibits self-induced metabolism of 1,25-dihydroxyvitamin D3 and amplifies 1,25-dihydroxyvitamin D3 receptor up-regulation in rat osteosarcoma cells. Arch Biochem Biophys 1989; 272:459-65.
46. Hayes ME, Bayley D, Mawer EB, Metabolism of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 and its sensitivity to ketoconazole in 1α,25-dihydroxyvitamin D3-differentiated HL60 cells. J Mol Endocrinol 1989;3: 199-205.
47. Zhao J, Tan BK, Marcelis S, Verstuyf A, Bouillon R. Enhancement of antiproliferative activity of 1α,25-dihydroxyvitamin D3 (analogs) by cytoehrome P450 enzyme inhibitors is compound- and cell-type specific. J Steroid Biochem Mol Biol 1996;57:197-202.
48. Rigby WF, Noelle RJ, Krause K, Fanger MW. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J Immunol 1985;135:2279-86.
49. Harris R, Ralph P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leukoc Biol 1985;37: 407-22.
50. Ayer DE, Eisenman RN. A switch from Myc:Max to Mad:Max hetero-complexes accompanies monocyte/macrophage differentiation. Genes Dev 1993;7:2110-9.
51. Chin L, Schreiber-Agus N, Pellicer I, Chen K, Lee HW, Dudast M, et al. Contrasting roles for Myc and Mad proteins in cellular growth and differentiation. Proc Natl Acad Sci U S A 1995;92:8488-92.
52. Meichle A, Philipp A, Eilers M, The functions of Myc proteins. Biochem Biophys Acta 1992;1114:129-46.
53. Heyns W, Drochmans A, van der Schueren E, Verhoeven G. Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer. Acta Endocrinol 1985;110:276-83.
54. Rigas JR, Francis PA, Muindi JR, Kris MG, Huselton C, DeGrazia F, et al. Constitutive variability in the pharmacokinetics of the natural retinoid all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Inst 1993;85:1921-6.